Recombinant and tissue extract thromboplastins for determination of international normalised ratio in over-anticoagulated patients.
The international normalised ratio (INR)/international sensitivity index (ISI) system is established for calibration of thromboplastins for laboratory monitoring of oral anticoagulant therapy. The calibration procedure employs patients stabilised on oral anticoagulants, and is therefore validated for patients within the therapeutic range. For practical reasons, the system is used for patients at all levels of therapy, including over-anticoagulated patients with particularly low levels of factors II, VII and X. We studied patients within and above the therapeutic range, using a thromboplastin containing recombinant human tissue factor (Innovin) and two tissue extract thromboplastins. In samples with INRs from 2.0 to 4.0, there was good agreement between results obtained with the three systems (mean INRs within 4% of each other). In patients with INRs > 4.0, results with a human placental extract reagent (Thromborel S) were similar to those obtained with a rabbit brain thromboplastin (IL PT Fib Hs Plus); mean INRs were 6.30 and 6.32 respectively (not significant). Results with Innovin (mean INR: 7.67) were significantly (P < 0.001) greater (on average by 22%) than those obtained with the other two materials. The discrepancy between results with different reagents negatively correlated with factor VII levels. Thus, the lower the factor VII level, the greater was the discrepancy between INRs. Unexpectedly, there was a positive correlation between factor V level and the difference between INRs with different reagents. Thus, the higher the factor V level, the greater was the discrepancy between INRs. The effect of these differences at higher INRs on patient management is unknown, but the recently revised UK guidelines recommend that management of these patients should be influenced by clinical factors, reducing the relative importance of discrepancies between results obtained with different systems.
Watson
C
C
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, UK.
Kitchen
S
S
Woolley
A M
AM
Young
L
L
Malia
R G
RG
D000925:Anticoagulants / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D006490:Hemostatics; D006801:Humans; D019934:International Normalized Ratio / Q000379:methods*; D011994:Recombinant Proteins; D013925:Thromboplastin
D000925:Anticoagulants; D006490:Hemostatics; D011994:Recombinant Proteins; D013925:Thromboplastin